STOCK TITAN

[144] UroGen Pharma Ltd. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mark Schoenberg filed a notice of proposed sale of restricted securities under Rule 144. The filing covers 13333 ordinary shares to be sold through Oppenheimer & Co. Inc., with an aggregate market value of 261460.13, on or about 02/02/2026 on the Nasdaq exchange.

The shares were acquired through restricted stock unit (RSU) grants from the issuer between 2023 and 2025. The notice also reports a prior sale of 10000 ordinary shares on 11/19/2025 for gross proceeds of 250005.00. By signing, the seller represents having no undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Urogen Pharma

NASDAQ:URGN

URGN Rankings

URGN Latest News

URGN Latest SEC Filings

URGN Stock Data

936.18M
44.31M
6.87%
98.61%
15.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
RA'ANANA